Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?-Reference-Cited by-同舟云学术

Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?

Published:2018-08 Issue:4 Volume:23 Page:239-247
ISSN:1092-8529
Container-title:CNS Spectrums
language:en
Short-container-title:CNS Spectr.

Author:

Stahl Stephen M.

Abstract

The two approved treatments for tardive dyskinesia both inhibit the vesicular monoamine transporter type 2 (VMAT2) yet have pharmacologic properties that distinguish one from the other. Knowing these differences may help optimize which treatment to select for individual patients.

Publisher

Cambridge University Press (CUP)

Subject

Psychiatry and Mental health,Neurology (clinical)

Reference20 articles.

1. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects

2. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites

3. VMAT2 inhibitors for the treatment of tardive dyskinesia

4. AUSTEDO (deutetrabenazine) Clinical Pharmacology. US Food & Drug Administration. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). AUSTEDO. May 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082orig1s000clinpharmr.pdf (accessed June 1, 2018).

5. Liquid chromatography-tandem mass spectrometric assay for the determination of tetrabenazine and its active metabolites in human plasma: a pharmacokinetic study

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease;Expert Review of Neurotherapeutics;2024-07-09

2. Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis;Psychopharmacology;2024-01-19

3. Treatments for Medication-Induced Movement Disorders;Tasman’s Psychiatry;2024

4. Treatments for Medication-Induced Movement Disorders;Tasman’s Psychiatry;2023

5. Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine;Clinical Pharmacology in Drug Development;2022-12-18